PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70) 14

Applicant's or agent's file reference	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
D 2758		
International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/EP00/08711	06/09/2000	06/09/1999
International Patent Classification (IPC) or national classification and IPC C07K16/00		
Applicant DIETRICH, Daniel R.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 6 sheets, including this cover sheet.

   ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of 3 sheets.

3. This report contains indications relating to the following items:

   - I ☒ Basis of the report
   - II ☐ Priority
   - III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
   - IV ☐ Lack of unity of invention
   - V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations suporting such statement
   - VI ☐ Certain documents cited
   - VII ☒ Certain defects in the international application
   - VIII ☒ Certain observations on the international application

Date of submission of the demand	Date of completion of this report
14/02/2001	19.07.2001
Name and mailing address of the international preliminary examining authority: European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Thiele, U Telephone No. +49 89 2399 8643

Form PCT/IPEA/409 (cover sheet) (January 1994)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP00/08711

I. Basis of the report

1. With regard to the **elements** of the international application *(Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17))*:
Description, pages:

1-31	as originally filed				

Claims, No.:

1-18	as received on	27/06/2001	with letter of	27/06/2001	

Drawings, sheets:

1/7-7/7	as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

   These elements were available or furnished to this Authority in the following language: , which is:

   - ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
   - ☐ the language of publication of the international application (under Rule 48.3(b)).
   - ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

   - ☐ contained in the international application in written form.
   - ☐ filed together with the international application in computer readable form.
   - ☐ furnished subsequently to this Authority in written form.
   - ☐ furnished subsequently to this Authority in computer readable form.
   - ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
   - ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

   - ☐ the description, pages:
   - ☐ the claims, Nos.:

☐ the drawings, sheets:

5. ☒ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)
see separate sheet

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	1-18
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-18
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-18
	No:	Claims	

2. Citations and explanations
see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

Section I

The amendments filed with the letter of 27.06.01 introduce subject-matter which extends beyond the content of the application as filed, contrary to Article 34(2)(b) PCT. The amendments concerned are the following:

- "comprising" (claim 1);

it would appear that the application as originally filed merely provides support for a term such as "consisting essentially of" (see page 5, lines 12 - 14). The current examination was carried out on the basis of the latter terminology.

Section III

Although, in conformity with the information given on PCT/ISA form 210, box I.2, the international search report was drafted only for those parts of claims 1 - 17 as originally filed which appear to be clear, supported and disclosed, namely those parts relating to compounds which are antibodies, which have a binding site for a group represented by formula (I) as on page 1 of the description, e.g. as disclosed in the description at pages 18, line 26 - page 25, line 10, the search is considered by this IEA to be complete for claims 1 - 18 on file.

Section V

1) Reference is made to the following documents:

D1: ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 96, 1996, page 380
D2: NATURAL TOXINS, vol. 3, no. 2, 1995, pages 78-86
D3: JOURNAL OF AOAC INTERNATIONAL, vol. 80, no. 2, 1997, pages 408-417, Arlington, VA, USA
D4: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 110, no. 25, 7 December 1988, pages 8557-8558, Washington, DC, USA cited in the application
D5: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 118, no. 47, 27

November 1996, pages 11759-11770, Washington, DC, USA cited in the application
D6: WATER RESEARCH, vol. 34, no. 10, July 2000, pages 2761-2769, Amsterdam, The Netherlands

2) The subject-matter of claim 1, and claims 2 - 8 as dependent thereon would appear to be novel and inventive over the known state of the art (Art. 33(2), (3) PCT).

The arguments submitted in this respect by the applicant in response to the Written Opinion can essentially be accepted.

D4 and D5 merely relate to the structure of microcystin congeners.

In addition, it would appear that none of documents D1 - D3 discloses antibodies having a binding site for the group represented by formula (I) of present claim 1, the so-called ADDA group.

Each of D1 - D3 discloses antibodies raised against complete microcystin-LR (MC-LR) molecules and not against the isolated ADDA group. Since moreover D1 - D3 report extreme variations in cross-reactivities of the antibodies with respect to various nodularin and microcystin congeners which contain the ADDA group, it can be reasonably assumed that each of said antibodies contains an epitope which may overlap with the ADDA moiety but which also interacts with other groups present in the complete MC-LR. It can be acknowledged that in view of the above, the statement by the authors of D2 on page 84, l. col., first full paragraph , "the protective activities of the MAbs, along with their specific binding to the ADDA portion, support the importance of ADDA as the key functional domain of the microcystins" is not supported by the experimental data in this publication, but a mere assumption. Another pointer to novelty of the subject-matter of claim 1 is the statement in D2 that the alteration of the variable Arg residue in microcystins, a position remote from the ADDA group, reduces the ability of the reported monoclonal antibodies to recognize microcystin cyclic peptides with high specificity (see D2, paragraph bridging pages 83 and 84).

In the absence of further guidance, the skilled person, being equipped with the teaching of the known prior art would also have had no motivation to produce antibodies or analogs directed against the ADDA group.

Since finally, the applicant with the letter responsive to the Written Opinion has submitted further experimental data which show that the compounds of the present invention advantageously display low variation in cross-reactivity across a very broad range of microcystin congeners as well as excellent quantification characteristics when employed in, e.g., a competitive ELISA (see also pages 24 and 25, Fig. 5 of the instant application), the addition to novelty, the presence of inventiveness can be acknowledged.

3) Claims 9 - 18 relate to methods for preparing and uses of the novel and inventive compounds of the invention, or relate back thereto.

Thus, also for said claims the requirements of Arts. 33(2) and (3) PCT are met.

Section VII

Contrary to the requirements of Rule 5.1(a)(ii) PCT, the relevant background art disclosed in the documents D1 - D3 is not mentioned in the description, nor are these documents identified therein.

Section VIII

The term "kit" in claim 13, which lists merely one specific component and encompasses further unspecified components renders the scope for which protection is sought unclear (Art. 6 PCT; Rule 6(3) PCT).

Application No.: PCT/EP00/08711
Applicant: Prof. Dr. Daniel R. Dietrich
New Zealand Agricultural Research Institute Limited
"Congener Independent Detection Of Microcystin And Nodularin Congeners"
Our Ref: D 2758 - py / js

Claims

1. A compound comprising one or more polypeptides providing a binding site of a monoclonal, polyclonal or recombinant antibody or a functionally active derivative or part thereof for a group represented by the following formula (I)



(I)

which is part of a toxin derived from a cyanobacterium, wherein
group R^1 represents a halogen atom, $-OSO_3$, -OR' or $-NR'_2$ and
group R^2 represents hydrogen, (C_1-C_4)alkyl, (C_1-C_4)alkoxy, (C_1-C_4)acyl, (C_1-C_4)aminoacyl or (C_1-C_4)carboxyaminoacyl,
or the groups R^1 and R^2 are connected to each other to form a cyclic moiety,
the groups R^3 which may be the same or different are each independently selected from the group consisting of hydrogen and (C_1-C_4)alkyl,
group R^4 represents (C_1-C_4)alkoxy,
and wherein the phenyl group may be substituted or unsubstituted.

2. The compound according to claim 1, wherein the groups R' represent independently from each other hydrogen, substituted or unsubstituted (C_1-C_4)alkyl or (C_1-C_4)acyl, when bound to nitrogen.

3. The compound according to claim 1 or 2, wherein the groups R^3 each represent methyl and group R^4 represents methoxy.

4. The compound according to any one of claims 1 to 3, wherein group R^1 represents aminoacyl and group R^2 represents (C_1-C_4)acyl.

5. The compound according to claim 4, wherein group R^1 represents glycyl or D-alanyl and group R^2 represents acetyl.

6. The compound according to any one of claims 1 to 5, wherein group R^1 represents $-NH_2$ and group R^2 represents glutamidyl or 2-aminopropionamidyl.

7. The compound according to any one of claims 1 to 6, wherein the toxin is selected from the group consisting of mycrocystin and nodularin congeners.

8. The compound according to any one of claims 1 to 7 which is a polyclonal, monoclonal or recombinant antibody or a functionally active derivative or fragment thereof.

9. A method for the preparation of the compound according to any one of claims 1 to 8 comprising the steps of

(a) preparing a compound containing a group represented by formula (I) as defined in any one of claims 1 to 7,

(b) coupling the compound of step (a) to a carrier.

incomplete for prep. AB

10. The method according to claim 9, wherein the carrier is a polymeric substance.

11. The method according to claim 10, wherein the polymeric carrier is selected from the group consisting of polyethyleneglycol, polypeptides, proteins, polysaccharides or plastic supports.

12. The method according to claim 11, wherein the protein carrier is selected from bovine serum albumin, ovalbumin, cationised bovine serum albumin or horseradish peroxidase.

13. The method according to any one of claims 9 to 12 which further comprises the steps of

(c) immunizing an animal with the conjugate obtained in step (b), and

(d) isolating the animal's blood, blood serum and/or spleenocytes.

14. A diagnostic kit containing the compound according to any one of claims 1 to 8.

15. An affinity matrix containing the compound according to any one of claims 1 to 8 coupled to a polymeric resin.

16. Use of the compound according to any one of claims 1 to 8 for the detection of a compound containing the group represented by the formula (I).

17. A method for concentrating a compound containing the group represented by the formula (I) from a fluid or for substantially decreasing the amount of a compound containing the group represented by the formula (I) in a fluid comprising the steps of

(a) preparing the compound according to any one of claims 1 to 8,

(b) coupling the compound obtained in step (a) to a polymeric matrix, and

(c) contacting the fluid with the polymeric matrix obtained in step (b).

18. The method according to claim 17, wherein the fluid is hemodialysis water, drinking water or water derived from rivers, lakes and oceans.

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

Commissioner
US Department of Commerce
United States Patent and Trademark Office, PCT
2011 South Clark Place Room CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 15 June 2001 (15.06.01)	
International application No. PCT/EP00/08711	**Applicant's or agent's file reference** D 2758
International filing date (day/month/year) 06 September 2000 (06.09.00)	**Priority date** (day/month/year) 06 September 1999 (06.09.99)
Applicant DIETRICH, Daniel, R. et al	

1. The designated Office is hereby notified of its election made:

   [X] in the demand filed with the International Preliminary Examining Authority on:

   14 February 2001 (14.02.01)

   [ ] in a notice effecting later election filed with the International Bureau on:

2. The election [X] was

   [ ] was not

   made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO **34, chemin des Colombettes** **1211 Geneva 20, Switzerland**	Authorized officer Claudio Borton
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF THE RECORDING OF A CHANGE

(PCT Rule 92bis.1 and Administrative Instructions, Section 422)

To:

PERREY, Ralf
Müller-Boré & Partner
Grafinger Strasse 2
D-81671 München
ALLEMAGNE

Date of mailing (day/month/year)
12 March 2002 (12.03.02)

Applicant's or agent's file reference
D 2758

IMPORTANT NOTIFICATION

International application No.
PCT/EP00/08711

International filing date (day/month/year)
06 September 2000 (06.09.00)

1. The following indications appeared on record concerning:

[X] the applicant [X] the inventor [ ] the agent [ ] the common representative

Name and Address
TOWERS, Noale
27 Mansel Avenue
Hillcrest
Hamilton
New Zealand

State of Nationality: NZ
State of Residence: NZ
Telephone No.:
Facsimile No.:
Teleprinter No.:

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

[ ] the person [X] the name [ ] the address [ ] the nationality [ ] the residence

Name and Address
TOWERS, Neale, R.
27 Mansel Avenue
Hillcrest
Hamilton
New Zealand

State of Nationality: NZ
State of Residence: NZ
Telephone No.:
Facsimile No.:
Teleprinter No.:

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

[X] the receiving Office
[ ] the International Searching Authority
[ ] the International Preliminary Examining Authority
[ ] the designated Offices concerned
[X] the elected Offices concerned
[ ] other:

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Facsimile No.: (41-22) 740.14.35

Authorized officer
Marie-José DEVILLARD
Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING OF A CHANGE

(PCT Rule 92bis.1 and Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

PERREY, Ralf
Müller-Boré & Partner
Grafinger Strasse 2
D-81671 München
ALLEMAGNE

Date of mailing (day/month/year)
01 May 2001 (01.05.01)

Applicant's or agent's file reference
D 2758

IMPORTANT NOTIFICATION

International application No.
PCT/EP00/08711

International filing date (day/month/year)
06 September 2000 (06.09.00)

1. The following indications appeared on record concerning:

[X] the applicant [X] the inventor [ ] the agent [ ] the common representative

Name and Address
DIETRICH, Daniel, R.
Obere Bündt 4
D-78465 Wallhausen
Germany

State of Nationality: CH
State of Residence: DE
Telephone No.:
Facsimile No.:
Teleprinter No.:

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

[ ] the person [ ] the name [X] the address [ ] the nationality [ ] the residence

Name and Address
DIETRICH, Daniel, R.
Unterdorf
CH-8566 Neuwilen
Switzerland

State of Nationality: CH
State of Residence: CH
Telephone No.:
Facsimile No.:
Teleprinter No.:

3. Further observations, if necessary:

4. A copy of this notification has been sent to:

[X] the receiving Office
[ ] the International Searching Authority
[ ] the International Preliminary Examining Authority
[X] the designated Offices concerned
[ ] the elected Offices concerned
[ ] other:

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Facsimile No.: (41-22) 740.14.35

Authorized officer
F. Baechler
Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	**FOR FURTHER ACTION** see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
D 2758		
International application No.	International filing date *(day/month/year)*	(Earliest) Priority Date *(day/month/year)*
PCT/EP 00/ 08711	06/09/2000	06/09/1999
Applicant		
DIETRICH, Daniel R.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 5 sheets.

[X] It is also accompanied by a copy of each prior art document cited in this report.

1. **Basis of the report**

   a. With regard to the **language,** the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

   [ ] the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

   b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

   [ ] contained in the international application in written form.

   [ ] filed together with the international application in computer readable form.

   [ ] furnished subsequently to this Authority in written form.

   [ ] furnished subsequently to this Authority in computer readble form.

   [ ] the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

   [ ] the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. [X] **Certain claims were found unsearchable** (See Box I).

3. [ ] **Unity of invention is lacking** (see Box II).

4. With regard to the **title,**

   [X] the text is approved as submitted by the applicant.

   [ ] the text has been established by this Authority to read as follows:

5. With regard to the **abstract,**

   [X] the text is approved as submitted by the applicant.

   [ ] the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No. _____

   [ ] as suggested by the applicant.

   [ ] because the applicant failed to suggest a figure.

   [ ] because this figure better characterizes the invention.

   [X] None of the figures.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-17 relate to proteinaceous compounds, or functional derivatives thereof, which have only been defined by reference to a desirable characteristic or property, namely having a binding site for a group represented by formula (I) as on page 1 of the description, lacking any other definition, e.g. of a structural nature, which would allow a complete search for said group of compounds.
The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds which are antibodies, which have a binding site for a group represented by formula (I) as on page 1 of the description, e.g. as disclosed in the description at pages 18, line 26 till page 25, line 10.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 00/08711

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07K16/12 G01N33/577 G01N33/68 C07K17/02 C07K1/22

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
BIOSIS, EMBASE, WPI Data, PAJ, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	X. HUANG ET AL.: "Production and characterization of monoclonal antibodies against the blue-green algal toxin microcystin." ABSTRACTS OF THE GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 96, 1996, page 380 XP000982157 USA abstract P-64 ---	1-17
X	S. NAGATA ET AL.: "Novel monoclonal antibodies against microcystin and their protective activity for hepatotoxicity." NATURAL TOXINS, vol. 3, no. 2, 1995, pages 78-86, XP000982191 New York, NY, USA the whole document --- -/--	1-17

[X] Further documents are listed in the continuation of box C.

[ ] Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
16 February 2001	01/03/2001

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Nooij, F

2

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	S. NAGATA ET AL.: "Enzyme immunoassay for direct determination of microcystins in environmental water." JOURNAL OF AOAC INTERNATIONAL, vol. 80, no. 2, 1997, pages 408-417, XP000982223 Arlington, VA, USA abstract page 413, right-hand column, line 28 -page 414, left-hand column, line 8 figure 1	1-17
A	K. RINEHART ET AL.: "Nodularin, microcystin, and the configuration of Adda." JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 110, no. 25, 7 December 1988 (1988-12-07), pages 8557-8558, XP002160425 Washington, DC, USA cited in the application the whole document	1-17
A	J. HUMPHREY ET AL.: "Total synthesis of the serine-threonine phosphatase inhibitor microcystin-LA." JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 118, no. 47, 27 November 1996 (1996-11-27), pages 11759-11770, XP002160426 Washington, DC, USA cited in the application scheme 1 page 11760, left-hand column	1-17
P,X	J. METCALF ET AL.: "Production of novel polyclonal antibodies against the cyanobacterial toxin microcystin-LR and their application for the detection and quantification of microcystins and nodularin." WATER RESEARCH, vol. 34, no. 10, July 2000 (2000-07), pages 2761-2769, XP004203376 Amsterdam, The Netherlands abstract figure 1; table 1 conclusions	1-17

2

Applicant: Prof. Dr. Daniel R. Dietrich et al.
" Congener Independent Detection Of Microcystin And Nodularin Congeners "
Our Ref: D 2681EU - py / js

Claims

1. A proteinaceous compound or functionally active derivative or part thereof having a binding site for a group represented by the following formula (I)



(I)

which is part of a toxin derived from a cyanobacterium, wherein
group R^1 represents a halogen atom, $-OSO_3$, -OR' or $-NR'_2$ and
group R^2 represents hydrogen, (C_1-C_4)alkyl, (C_1-C_4)alkoxy, (C_1-C_4)acyl, (C_1-C_4)aminoacyl or (C_1-C_4)carboxyaminoacyl,
or the groups R^1 and R^2 are connected to each other to form a cyclic moiety,
the groups R^3 which may be the same or different are each independently selected from the group consisting of hydrogen and (C_1-C_4)alkyl,
group R^4 represents (C_1-C_4)alkoxy,
and wherein the phenyl group may be substituted or unsubstituted.

2. The proteinaceous compound of claim 1, wherein the groups R' represent independently from each other hydrogen, substituted or unsubstituted (C_1-C_4)alkyl or (C_1-C_4)acyl, when bound to nitrogen.

3. The proteinaceous compound of claim 1 or 2, wherein the groups R^3 each represent methyl and group R^4 represents methoxy.

4. The proteinaceous compound according to any one of claims 1 to 3, wherein group R^1 represents aminoacyl and group R^2 represents (C_1-C_4)acyl.

5. The proteinaceous compound of claim 4, wherein group R^1 represents glycyl or D-alanyl and group R^2 represents acetyl.

6. The proteinaceous compound according to any one of claims 1 to 5, wherein group R^1 represents $-NH_2$ and group R^2 represents glutamidyl or 2-aminopropionamidyl.

7. The proteinaceous compound according to any one of claims 1 to 6, wherein the toxin is selected from the group consisting of mycrocystin and nodularin congeners.

8. The proteinaceous compound according to any one of claims 1 to 7 which is a polyclonal, monoclonal or recombinant antibody or a functionally active derivative or fragment thereof.

9. A method for the preparation of the proteinaceous compound according to any one of claims 1 to 8 comprising the steps of
   (a) preparing a compound containing a group represented by formula (I) as defined in any one of claims 1 to 7, and
   (b) coupling the compound of step (a) to a carrier.

10. The method of claim 9, wherein the carrier is selected from the group consisting of polyethyleneglycol, polypeptides, proteins, polysaccharides or plastic supports.

11. The method of claim 10, wherein the protein carrier is selected from bovine serum albumin, ovalbumin, cationised bovine serum albumin or horseradish peroxidase.

12. The method according to any one of claims 9 to 11 which further comprises the steps of
   (c) immunizing an animal with the conjugate obtained in step (b), and
   (d) isolating the animal's blood, blood serum and/or spleenocytes.

13. A diagnostic kit containing the proteinaceous compound according to any one of claims 1 to 8.

14. An affinity matrix containing the proteinaceous compound according to any one of claims 1 to 8 coupled to a polymeric resin.

15. Use of the proteinaceous compound according to any one of claims 1 to 8 for the detection of a compound containing the group represented by the formula (I).

16. A method for concentrating a compound containing the group represented by the formula (I) from a fluid or for substantially decreasing the amount of a compound containing the group represented by the formula (I) in a fluid comprising the steps of

(a) preparing the proteinaceous compound according to any one of claims 1 to 8,

(b) coupling the compound obtained in step (a) to a polymeric matrix, and

(c) contacting the fluid with the polymeric matrix obtained in step (b).

17. The method of claim 16, wherein the fluid is hemodialysis water, drinking water or water derived from rivers, lakes and oceans.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 March 2001 (15.03.2001)

PCT

(10) International Publication Number
WO 01/18059 A2

(51) International Patent Classification[7]: C07K 16/00

(21) International Application Number: PCT/EP00/08711

(22) International Filing Date:
6 September 2000 (06.09.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
99116881.6 6 September 1999 (06.09.1999) EP

(71) Applicants *(for all designated States except US)*: THE REGENT OF THE UNIVERSITY OF CALIFORNIA [US/US]; 111 Franklin Street, 12th Floor, Oakland, CA 94607-5200 (US). NEW ZEALAND AGRICULTURAL RESEARCH [NZ/NZ]; Institute Limited, Private Bag 3115, Hamilton (NZ).

(71) Applicant and
(72) Inventor: DIETRICH, Daniel, R. [CH/DE]; Obere Bündt 4, D-78465 Wallhausen (DE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: FISCHER, Werner [DE/CH]; Le Grand Chemin 132, CH-1066 Epalinges (CH). CHAMBERLIN, Richard [US/US]; 24 Mendel Ct., Irvine, CA 92612 (US). AGGEN, James, B. [US/US]; 1080 Eddy St. #501, San Francisco, CA 94109 (US). GARTHWAITE, Ian [GB/NZ]; 16 Fairview Street, Hamilton (NZ). MILES, Christopher, O. [NZ/NO]; Langsetveien 8, Kjelsas, N-0495 Oslo (NO). ROSS, Kathryn, M. [NZ/NZ]; 20 Galway Avenue, Hamilton (NZ). TOWERS, Noale [NZ/NZ]; 27 Mansel Avenue, Hillcrest, Hamilton (NZ).

(74) Agent: PERREY, Ralf; Müller-Boré & Partner, Grafinger Strasse 2, D-81671 München (DE).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:
— *Without international search report and to be republished upon receipt of that report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/18059 A2

(54) Title: CONGENER INDEPENDENT DETECTION OF MICROCYSTIN AND NODULARIN CONGENERS



(I)

(57) Abstract: The present invention relates to a proteinaceous compound or functionally active derivative or part thereof having a binding site for a group represented by formula (I) which is part of a group of toxins derived from various cyanobacteria, to a method for its production, to diagnostic kits and to an affinity matrix (e.g. for use in immunoaffinity columns, on-line detection and purifications devices) containing the proteinaceous compound as well as to methods for substantially decreasing the amount of a compound containing the group represented by formula (I) in fluids or for concentrating compounds, e.g. toxins, containing the group represented by formula (I) from fluids such as crude water samples, extracts of algae or other tissue samples, e.g. to determine toxin concentrations.

"Congener Independent Detection Of Microcystin And Nodularin Congeners"

Description

The present invention relates to a proteinaceous compound or functionally active derivative or part thereof having a binding site for a group represented by the following formula (I)



(I)

which is part of a group of toxins derived from various cyanobacteria, to a method for its production, to a diagnostic kits and to an affinity matrix (e.g. for use in immunoaffinity columns, online detection and purification devices) containing the proteinaceous compound as well as to methods for substantially decreasing the amount of a compound containing the group represented by formula (I) in fluids or for concentrating compounds, e.g. toxins, containing the group represented by formula (I) from fluids such as crude water samples, extracts of algae or other tissue samples, e.g. to determine toxin concentrations.

Due to increasing settlement, industrialisation and intensive agriculture wide spread problems of water pollution have arisen. This water pollution and the following eutrophication has led in many cases to the development of blooms of blue-green algae (i.e. cyanobacteria). The environmental factors which are responsible for the development of such blooms of cyanobacteria are up to now almost unknown. In general, blooms of cyanobacteria can be found in eutrophic bodies of water, e.g. under such conditions as relatively high nutrient levels (phosphate and nitrate), water temperatures of between 15 to 30°C and pH-values of between 6 and 9 or higher (Wicks et al., 1990).

A severe problem of the development of blooms of cyanobacteria is that cyanobacteria produce a broad variety of toxic substances. Accordingly, since the end of the last century there has been an increasing number of cases of intoxication and even deaths of humans, animals, especially birds and fishes, which could be demonstrated to be caused by the use of water which was contaminated with cyanobacteria after chlorination and filtration for medical purposes (cases of deaths in the dialysis centers of Caruaru, Brazil, 1996 and Evora, Portugal, 1995), by the consumption of contaminated drinking water or even of clumps of cyanobacteria themselves (Francis, 1878; Falconer et al., 1983; Carmichael, 1984; Beasley et al., 1989; Mahmod et al., 1988; Skolberg et al. 1984).

The toxin producing cyanobacteria can be subdivided into species which synthesize mostly hepatotoxic peptides such as *Microcystis* sp., *Nodularia* sp. and *Oszillatoria* sp., and other genus which produce mostly neurotoxic alkaloids such as *Anabaena* and *Aphanizomenon* (Carmichael et al., 1990). Studies of different strains of *M.aeruginosa* revealed that, depending on strain and habitat, the cyanobacteria produce different congeners and amounts of a toxin (Sivonen et al., 1992 a-c).

Cyanobacteria can secrete the intracellularly produced toxins into the surrounding water (Watanabe et al., 1992 a,b). Further studies showed that the microcystin congener microcystin-LR is photostable, however, it can be microbially degraded (Watanabe et al., 1992 a; Tsuji et al., 1994; Cousins et al., 1996). Under aerobic conditions and in culture media which were inoculated with bacteria, the half-lifetimes of microcystin-LR and -YR were more than 45 days (Watanabe et al., 1992 a). In contrast, half-lifetimes of less than 5 days were determined in seawater (Cousins et al., 1996). Under unfavorable conditions (i.e. cold temperatures and minimal presence of specific populations of microbes) microcystins may persist several days to even months and, therefore, may represent a potential danger for humans via the drinking water supply.

Accordingly, the increased incidence of gastroenteritis and liver carcinomas in humans has been attributed to the consumption of drinking water which was

contaminated with cyanobacterial hepatoxins (in particular microcystin-LR) in several studies, although a direct relation between chronic microcystin-LR exposure and the development of liver carcinomas has not yet been proven (Tisdale, 1931; Keleti et al., 1981; Billings, 1981). Clinical indications of microcystin toxicoses in mammals is characterized by weakness, anorexia, mucous pallor, muscle termor, forced expirations and death by hypovolemic shock which is caused by intrahepatic hemorrhagia and/or liver failure (Theiss et al., 1988; Jackson et al., 1984).

Mammals seem to take up microcystin orally, and the toxin reaches the liver with the blood via a highly specific transporter mechanism (organic anion carrier) (Eriksson et al, 1990; Hooser et al., 1990; Runnegar et al., 1991). One molecular mechanism of the serious effects of microcystin seems to be its binding to the catalytic subunit of proteinphosphatases 1 and 2A which leads to their inhibition (Eriksson et al., 1990; Yoshezawa et al., 1990; Matsushima et al., 1990; Honkanen et al., 1990; McKintosh et al., 1990; McKintosh et al., 1995; Runnegar et al., 1996). After accute intoxication of high microcystin concentrations, the inhibition of proteinphosphatases leads to hyperphosphorylation of intermediate filaments which, in turn, is followed by collapse of the cytoskeleton, loss of the cells' structure, extensive intrahepatic hemorrhage and necrosis of the hepatocytes (Eriksson et al., 1990; Falconer et al., 1981, 1992). Similar to other proteinphosphatase inhibitors (e.g. calyculin-A, okadaic acid), the chronic exposure of mice to microcystin-LR leads to promotion of liver tumors (Falconer, 1991; Nishiwaki-Matsushima et al., 1992).

Due to the high toxicity and carcinogenicity of hepatotoxic cyanobacteria toxins and the potential chronic exposure of organisms (humans as well as animals) to these toxins via the drinking water there is an urgent need to detect toxic blooms of cyanobacteria early and to decrease the concentration of cyanobacteria toxins in drinking water.

Since it has been difficult to analytically and routinely detect the different microcystin and nodularin congeners with the required sensitivity (Kenefick et al., 1993; Lawton et al., 1994), prior art studies have concentrated on the destruction

of the cyanobacteria toxins during the drinking water purification process. Mostly, continuous methods have been studied which can be carried out under routine conditions such as sand filtration, binding to activated carbon and destruction by chlorination (James et al., 1994). However, these studies revealed that neither sand filtration nor chlorination, UV-irradiation, treatment with hydrogen peroxide or potassium permanganate nor filtration via activated carbon could substantially remove the cyanobacteria toxins from drinking water. In this case a further problem seems to be the treatment of the raw water which is contaminated with cyanobacteria. The chlorination or the treatment of the cyanobacteria with copper sulfate leads to the release of the cyanobacteria toxins which are present in the cytosol without destroying the toxins to even the lowest degree. Also, the chlorination of sand filtered water is ineffective. Only the filtration via activated carbon seems to be appropriate to remove a considerable amount (about 60% to 80%) of the toxins. However, this purification performance was only reached for a limited period of time due to a relatively quick saturation of the activated carbon particles. Therefore, after about 10,000 bed volumes (1 bed volume = volume of the activated carbon) the filters became leaky.

Therefore, the technical problem underlying the present invention is to provide a novel system for the reliable detection as well as the removal of all kinds of hepatotoxic cyanobacteria toxins such as microcystin and nodularin congeners, particularly in and from, drinking water and other sources.

The solution to the above problem is provided by the embodiments of the present invention as characterized in the claims.

In particular, the present invention relates to a proteinaceous compound or functionally active derivative or part thereof having a binding site for a group represented by the following formula (I)



(I)

which is part of a toxin derived from a cyanobacterium, wherein
group R^1 represents a halogen atom, preferably Br, $-OSO_3$, -OR' or $-NR'_2$
group R^2 represents hydrogen, (C_1-C_4)alkyl, (C_1-C_4)alkoxy, (C_1-C_4)acyl, (C_1-C_4)aminoacyl or (C_1-C_4)carboxaminoacyl,
or the groups R^1 and R^2 are connected to each other to form a cyclic compound,
the groups R^3 which may be the same or different are each independently selected from the group consisting of hydrogen and (C_1-C_4)alkyl,
group R^4 represents (C_1-C_4)alkoxy,
and wherein the phenyl group may be substituted or unsubstituted.

The term "proteinaceous compound or functionally active derivative or part thereof" means a compound which is capable of binding the above-described group of formula (I) and substantially consists of one or more polypeptides. The functionally active form of the proteinaceous compound according to the present invention may be a monomeric or a homo- or heterodimeric, -trimeric, -tetrameric or other oligomeric form.

The term "binding site" for the group as defined above means a three-dimensional arrangement of atoms of the above proteinaceous compound which is able to specifically interact with the group of formula (I) as defined above. The specific interaction may be any kind of chemical and/or physical interaction and comprises covalent binding, electrostatic interactions, hydrogen bonding, Van-der-Waals- as well as hydrophobic interactions.

Preferably, the group R' in the formula (I) represents independently from each other hydrogen, substituted or unsubstituted (C_1-C_4)alkyl or (C_1-C_4)acyl, when bound to nitrogen. According to a further preferred embodiment of the proteinaceous compound as defined above, the groups R^3 in the above formula (I) each represent methyl and group R^4 represents methoxy.

According to a further preferred embodiment of the proteinaceous compound of the present invention, group R^1 represents aminoacyl and group R^2 represents (C_1-C_4)acyl, or group R^1 represents glycyl or D-alanyl, respectively, and group R^2

represents acetyl, or group R^1 represents $-NH_2$ and group R^2 represents glutamidyl or 2-aminoproprionamidyl, respectively.

Preferably, the group represented by the above formula (I) is part of a toxin selected from the group consisting of microcystin and nodularin congeners. Microcystin (MC) and nodularin congeners are hereinafter referred to as microcystin-XY and nodularin-XY.

The chemical structures of *M. aeruginosa* and *Nodularia* sp.-hepatotoxins (i.e. microcystin-XY and nodularin-XY) are described in several prior art studies (Botes et al., 1982 a, d, 1994, 1985; Rinehard et al., 1988). Microcystin-XY and nodularin-XY are cyclic peptides consisting of seven or five, respectively, amino acids. The following formula represents microcystin-LR.



Nodularin-XY and microcystin-XY share the same specific characteristic amino acid (ADDA). The basic structure of microcystin-XY congeners consists of five non-variable amino acids: β-methylasparaginic acid, alanine, N-methyldehydroalanine, glutamate, and 3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienic acid (ADDA). The differences between individual microcystin congeners are based on the two variable L-amino acids which are, for

example, L-arginine and L-leucine in microcystin-LR and two times L-arginine in microcystin-RR, respectively. Normally, cyanobacteria produce a mixture of different forms of the toxins. The isolation of microcystin-XY from natural blooms of blue-green-algae resulted in up to six different microcystin congeners, and toxin concentrations up to 10 mg per g of dry mass of algae were determined (Wicks et al., 1990; Tsuji et al., 1994; Tencallar et al., 1994, 1995).

An especially preferred example of the proteinaceous compound according to the present invention is a polyclonal, monoclonal or recombinant antibody or a functionally active derivative or fragment thereof. The recombinant antibody may be produced by the translation and expression of any part of the genes coding for polyclonal or monoclonal antibodies and/or selection by screening of a phage display library using the group represent by the above formula (I).

The proteinaceous compound according to the present invention, e.g. a polyclonal, monoclonal or recombinant antibody or functionally active derivative or fragment thereof, has the advantage to be capable of binding to all congeners of the cyanobacterial hepatotoxins, e.g. microcystin and nodularin congeners which contain as a part of their structure the ADDA moiety.

In contrast to the proteinaceous compound of the present invention, the commercially available antibodies or ELISA kits, respectivley, are only capable of recognizing a very limited number of microcystin congeners. This means that the toxicity of blooms of cyanobacteria can be massively underdetermined by the use of the antibodies or kits, respectively, known so far.

A further embodiment of the present invention relates to a method for the preparation of the proteinaceous compound as defined above, comprising the steps of

a) preparing a compound containing a group represented by the formula (I) as defined above and

(b) coupling the compound of step (a) to a carrier.

The „carrier" is not particularly limited to a specific embodiment and may be, e.g. any polymeric substance. For example, carriers which are suitable for the above method may be selected from the group consisting of polyethyleneglycol, proteins, polypeptides, polysaccharides and solid phase supports such as plastic supports. Preferably, the protein carrier is selected from bovine serum albumin (BSA), ovalbumin (OVA) cationised bovine serum albumin (cBSA), and horseradish peroxidase (HRP).

In another preferred embodiment of the present invention, the above method further comprises the steps of

(c) immunizing an animal with the conjugate obtained in step (b) above and

(d) isolating the animal's blood, blood serum and/or spleenocytes.

In a further preferred embodiment, the above method further comprises the steps of preparing antisera from the animal's blood serum obtained in the above step (d) for the preparation of polyclonal antibodies. According to another preferred embodiment, the method of the present invention further comprises the steps of preparing monoclonal antibody-producing hybridoma cells from the animal's spleenocytes obtained in the above step (d). Yet another preferred embodiment of the above-defined method comprises the further steps of preparing recombinant antibodies including the isolation of the genetic material (DNA) from cells present in the animal's blood or from antibody-producing hybridoma cells.

A further embodiment of the present invention relates to a diagnostic kit containing the proteinaceous compound as defined above.

Another embodiment of the present invention relates to an affinity matrix containing the proteinaceous compound as defined above coupled to a polymeric resin.

The proteinaceous compound according to the present invention, e.g. a polyclonal, monoclonal or recombinant antibody or a functionally active derivative or fragment thereof as defined above, is particularly useful for the detection of a

compound containing the group represented by the above formula (I), for concentrating the toxins from crude extracts prior to analysis to determine toxin concentrations as well as to substantially decrease the amount of a compound containing the group represented by the formula (I) in a fluid, pharmaceutical or food preparation.

Therefore, a further embodiment of the present invention relates to a method for concentrating a compound containing the group represented by the formula (I), e.g. a toxin, from a fluid such as crude water samples, extracts of algae or other tissue samples, or for substantially decreasing the amount of a compound containing the group represented by the formula (I) in a fluid, e.g. water such as hemodialysis water, drinking water or water derived from rivers, lakes and oceans, comprising the steps of

(a) preparing the proteinaceous compound as defined above,

(b) coupling the compound obtained in step (a) to a polymeric matrix, and

(c) contacting the fluid with the polymeric matrix obtained in step (b).

Furthermore, the above method may also be applied to the cleaning of any other sources of cyanobacteria toxins such as, for example, food stuffs.

The Figures show:

Fig. 1 is a diagram showing a flow chart for the strategy of preparation of an anti-ADDA antibody according to the present invention.

Fig. 2 is a diagram showing preferred strategies for the coupling of an ADDA-hapten to a protein.

Fig. 3 shows several ADDA-derivatives which were synthesized for the production of the antibody useful for congener independent detection of microcystin and nodularin congeners.

Fig. 4 is a diagram showing the general principle of the indirect competitive microcystin enzyme-linked immunosorbent assay (MC-ELISA).

Fig. 5 is a diagram showing the crossreactivity with respect to different microcystin congeners (MC-LR, -RR and -YR) and nodularin of the anti-ADDA antibody (ADDA-824new, i.e. 26/06/00) raised in sheep which is directed against ADDA-HG coupled to ovalbumin.

Fig. 6 is a diagram showing the direct ELISA method and its sensitivity for detection of MC-YR. The anti-ADDA antibody (ADDA-825-$^{bleed,14/12/98}$) was raised in sheep and directed against ADDA-HG coupled to ovalbumin.

Fig. 7 is a diagram showing the indirect ELISA method using a monoclonal antibody and ist sensitivity for detection of MC-YR. The anti-ADDA antibody (ADDA-3G10B10) was raised in mice and directed against ADDA-HG coupled to ovalbumin.

The present invention is further illustrated by the following non-limiting examples.

EXAMPLE

ADDA hapten synthesis

The starting material N-Boc-ADDA-Me (**35**) was prepared by the published route: Humphrey, J. M.; Aggen, J.; Chamberlin, A. R. *J. Am Chem. Soc.* **1996**, *118*, 11759-11770. "Synthesis of the Serine-threonine Phosphatase Inhibitor Microcystin LA."



N-Boc-Adda-OMe (35) **N-Ac-Adda-OMe**

N-Ac-ADDA-OMe. To 31 mg (0.70 mmol) of **Boc-ADDA-OMe** in a flask was added 2 ml of TFA. After one hour the TFA was removed under vacuum, and the residue was concentrated three times from toluene to remove the TFA. The resulting oil was dissolved in 2.5 ml of freshly distilled CH_2Cl_2, and this was cooled to 0° C. 28 mg (0.28 mmol) of anhydrous triethylamine was added to the solution, followed by 0.141 g (1.39 mmol) of freshly distilled acetic anhydride. One hour later 5 ml of saturated NH_4Cl was added, and the mixture was stirred for 20 minutes at 0° C. The mixture was partitioned between water and EtOAc, and the phases were separated. The aqueous phase was extracted twice with EtOAc. The combined organic phases were washed once each with 50% saturated NH_4Cl, 50% saturated $NaHCO_3$, and brine, dried over $MgSO_4$, filtered, and concentrated under vacuum to give a white solid. The solid was purified via flash chromatography (1/1 EtOAc/hexanes) to give 25 mg (93%) of a white solid: R_f 0.23 (40:60 EtOAc:hexanes); IR (thin film) 3330, 2919, 1731, 1654, 1454 cm^{-1}; ^{1}H-NMR (500 MHz, $CDCl_3$) ‰ 0.99 (d, J = 6.5, 3H), 1.20 (d, J = 7, 3H), 1.57 (s, 3H), 2.02 (s, 3H), 2.58 (ddq, J = 6, 6.5, 10 Hz, 1H), 2.67 (dd J = 7.5, 14 Hz, 1H), 2.78 (obscured mult., 3H), 2.79 (dd, J = 5, 13.5 Hz, 1H), 3.17 (ddd, J = 5, 6, 7 Hz, 1H), 3.21 (s, 3H), 3.65 (s, 3H), 4.71 (ddd, J = 4.5,5,5.5 Hz, 1H), 5.37 (d, J = 9.5 Hz, 1H), 5.42 (dd, J = 15.5, 6.5 Hz, 1H), 6.18 (d, J = 15.5 Hz, 1H), 6.40 (d, J = 9 Hz, 1H), 7.25-7.15 (m, 5H); ^{13}C NMR (125 MHz, $CDCl_3$) ‰175.8, 169.5, 139.5, 136.6, 136.3, 132.4, 129.5, 128.2, 126.0, 124.9, 87.1, 58.6,_ 3.0, 51.7, 43.6, 38.4, 36.8, 23.5, 16.2, 14.9, 12.7; HRMS calculated for $C_{23}H_{34}NO_4$ $(M+H)^+$: 388.2488. Found: 388.2505.



N-Ac-Adda-OMe

N-Ac-Adda-OH (83)

N-Ac-ADDA-OH. To 22 mg (0.057 mmol) of the protected ADDA-derivative in 2 ml THF was added 0.57 ml (0.57 mmol) of 1 M LiOH. After 22 hours the mixture had clarified, and it was partitioned between hexanes and water. The phases were separated, and the aqueous phase was washed once with hexanes. The combined organic phases were back-extracted three times with water. The combined aqueous phases were acidified with 1 M $NaHSO_4$, and extracted three times with CH_2Cl_2. The combined CH_2Cl_2 phases were washed once with brine, filtered through cotton, and concentrated to give 23 mg of **83** as an oil that was taken on without purification: R_f 0.34 (1:49:50 HOAc:EtOAc:hexanes); IR (thin film) 3295 br, 2923, 1713, 1640 cm^{-1}; ^1H NMR (500 MHz, $CDCl_3$) ‰0.99 (d, J = 6.5, 3H), 1.25 (d, J = 7, 3H), 1.58 (s, 3H), 2.02 (s, 3H), 2.57 (ddq, J = 6.5, 6.5, 9.5 Hz, 1H), 2.65 (dd J = 7.5, 14 Hz, 1H), 2.76 (par.obsc. m, 3H), 2.77 (dd, J = 5, 13 Hz, 1H), 3.17 (ddd, J = 5, 6.5, 6.5 Hz, 1H), 3.21 (s, 3H), 4.71 (ddd, J = 5, 6, 10 Hz, 1H), 5.37 (d, J = 9.5 Hz, 1H), 5.45 (dd, J = 15.5, 6.5 Hz, 1H), 6.18 (d, J = 15.5 Hz, 1H), 6.37 (d, J = 9.5 Hz, 1H), 7.25-7.15 (m, 5H); HRMS calculated for $C_{22}H_{32}NO_4$ $(M+H)^+$: 374.2331, Found: 374.2325.



N-Ac-ADDA-D-Ala-OMe. To 17 mg (0.12 mmol) of D-Ala-OMe hydrochloride and 14 mg (0.036 mmol) of HATU in a flask was added 9 mg (0.024 mmol) of **83** in 0.6 ml DMF. The resulting solution was cooled to 0° C, and 41 mg (0.34 mmol) of collidine was added. The solution was stirred at 0° C for 2 hours, followed by warming to room temperature and stirring overnight. The mixture was partitioned between water and EtOAc, and the phases were separated. The aqueous phase was extracted once with EtOAc. The combined organic phases were washed once each with sat. $NaHCO_3$, water, 1 M $NaHSO_4$, water, and brine, dried over $MgSO_4$, filtered, and concentrated under vacuum to an off-white solid. Chromatography (80:20 EtOAc:hexanes) gave 8 mg (73%) of a white solid: R_f 0.17 (60:40 EtOAc:hexanes); IR (thin film) 3284, 3067, 2923, 1743, 1650, 1542 cm^{-1}; ^1H NMR (500 MHz, $CDCl_3$) ‰ 0.99 (d, J = 6.5, 3H), 1.23 (d, J = 7, 3H), 1.35 (d, J = 7 Hz, 3H), 1.58 (s, 3H), 2.04 (s, 3H), 2.52 (dq, J = 4, 7 Hz, 1H), 2.59 (ddq, J = 6.5, 7, 9.5 Hz, 1H), 2.68 (dd J = 7.5, 14 Hz, 1H), 2.81 (dd, J = 4.5, 14 Hz, 1H), 3.19 (ddd, J = 5, 7, 7 Hz, 1H), 3.22 (s, 3H), 3.75 (s, 3H), 4.55 (dq, J = 7, 7 Hz, 1H), 4.62 (m, 1H), 5.39 (d, J = 9.5 Hz, 1H), 5.45 (dd, J = 15.5, 6.5 Hz, 1H), 6.18 (d, J = 15.5 Hz, 1H), 6.23 (d, J = 7 Hz, 1H), 7.05 (d, J = 9 Hz, 1H), 7.27-7.17 (m, 5H); ^{13}C NMR (125 MHz, $CDCl_3$) ‰ 12.7, 15.4, 16.2, 18.4, 23.5, 36.7, 38.2, 44.4, 47.9, 52.6, 53.7, 58.6, 86.9, 125.2, 125.9, 128.2, 129.4, 132.2, 136.2, 139.4, 169.9, 173.2, 174.6; HRMS calculated for $C_{26}H_{39}N_2O_5$ $(M+H)^+$: 459.2859, Found: 459.2869.



N-Ac-ADDA-D-Ala-OH. To 5 mg (0.011 mmol) of N-Ac-ADDA-D-Ala-OMe in 1.75 ml of THF was added 0.10 ml (0.10 mmol) of 1 M LiOH. After 50 minutes, the mixture was partitoned between ether and water, and the phases were separated. The aqueous phase was washed once with ether. The combined etheral phases were back-extracted three times with water, and the combined aqueous phases were acidified to pH = 3 with saturated citric acid. The aqueous phases were then extracted twice with EtOAc, and the combined EtOAc phases were washed twice with water, once with brine, dried over $MgSO_4$, filtered, and concentrated *in vacuo*. The resulting solid was purified by preparative reversed-phase HPLC, retention time of product = 15.7 minutes (70 MeOH / 30 0.2% aq. TFA), to give 4 mg (85%) of the title compound as a white solid: R_f 0.36 (1 HOAc / 10 MeOH / 89 CH_2Cl_2); IR (thin film) 3288 br, 2937, 1720, 1658, 1632 cm^{-1}; ^1H NMR (500 MHz, DMSO-d_6) ‰ 0.94 (d, J = 7.0 Hz, 3H), 0.96 (d, J = 7.0 Hz, 3H), 1.19 (d, J = 7.0 Hz, 3H), 1.52 (s, 3H), 1.82 (s, 3H), 2.63 (dd, J = 7.0, 14.0 Hz, 1H), 2.73 (dd, J = 5.0, 14.0 Hz, 1H), 3.16 (s, 3H), 3.22 (ddd, J = 5.5, 5.5, 6.5 Hz, 1H), 4.19 (dq, J = 7.0, 7.5 Hz, 1H), 4.40 (m, 1H), 5.38 (d, J = 10.0 Hz, 1H), 5.44 (dd, J = 6.5, 16.0 Hz, 1H), 6.05 (d, J = 16.0 Hz, 1H), 7.17 (d, J = 7.5 Hz, 3H), 7.25 (t, J = 7.5 Hz, 2H), 7.60 (d, J = 9.0 Hz, 1H), 8.01 (d, J = 7.0 Hz, 1H); FAB MS calculated for $C_{25}H_{37}N_2O_5$ $(M+H)^+$: 445.2702. Found: 445.2695.

Coupling of hapten to proteins

Preparation of BSA–, cBSA–, and OVA–*N*-AcADDA-AlaOH.

BSA (10.6 mg), cationised BSA (cBSA) (10.0 mg), and OVA (8.3 mg) were each dissolved in PBS (1000 µl). Carbonyldiimidazole (19.81 mg, 0.12 mmol) was dissolved in dry DMF (500 µl), and a portion of the solution (100 µl) was added to *N*-acetyl-ADDA-D-Ala-OH (1.0 mg, 2.2 µmol) and allowed to stand for 90 min. DMF was added (BSA, 260 µl; cBSA, 260 µl; OVA, 280 µl) to the protein solutions just prior to addition of the activated ADDA-derivative. The solution of the activated ADDA-derivative (40 µl each to the BSA and cBSA, 20 µl to the OVA) was then added to the protein solutions, and the reaction was allowed to proceed at 4 °C for about 16 h. The resulting conjugates were repeatedly diluted and then concentrated by ultrafiltration (Filtron centrifugal ultrafiltration tubes, 10K cutoff) until the calculated dilution of unretained low molecular weight compounds was > 10^6.



N-Ac-Adda-D-Ala-Protein Conjugate

Preparation of HRP–MC-YR and aminoHRP.

Horse radish peroxidase (HRP) was oxidized by the method of Hermanson. HRP (19.73 mg, Boehringer) was dissolved in PBS and cooled to 4 °C. $NaIO_4$ (36.7 mg) was dissolved in water (2 ml), and 100 µl of this was added to the HRP solution, which rapidly became green. The reaction was held at 4°C in the dark for 20 min, then the HRP was separated from low molecular weight material by elution with PBS through a desalting column (Bio-Rad Econo-Pac 10DG).



To half of the oxidized HRP MC-YR-cysteamine (51 µg, see below) was added in MeOH (50 µl). To the other half diaminoethane hydrochloride (500 mg) was added in PBS (500 µl). $NaBH_3CN$ (16.4 mg) was dissolved in PBS (500 µl), and 100 µl of this was added to each HRP reaction (which immediately became crimson). After standing at 4 °C in the dark for about 16 h, the reactions were quenched by addition of diethanolamine in PBS (50 µl of 300 µl of diethanolamine in 5 ml PBS) and allowed to stand at 4°C in the dark for 2 h. The HRP solutions were then purified by passing through desalting columns (as above). The diaminethane conjugate (henceforth referred to as aminoHRP) and MC-YR conjugates were further purified by ultrafiltration to > 10^4 dilution (as above).

Preparation of HRP–, aminoHRP–, and OVA–ADDA-HG.

HRP, aminoHRP, and OVA were each dissolved in PBS (1 ml). To Me-ADDA-HG (0.67 mg) was added CDI (1.16 mg) in dry DMF (100 µl), and the reaction proceeded at ambient temperature 1.5 h whereupon dry DMF (150 µl) was added. A portion of this solution was added to the solutions of the proteins (50 µl to aminoHRP, 100 µl to HRP and OVA). DMSO (200 µl) was then added to the HRP and OVA reactions to assist in solubilising the reactants, and the three reactions were maintained at 4 °C in the dark for ca 16 h. The conjugates were then purified on the desalting column and then further purified by repeated ultracentrifugation to $> 3 \times 10^4$ dilution (as above).



Preparation of MC-YR–cysteamine conjugate



The method is based on those of Kondo et al. (1992) and Sherlock et al. (1998). Cysteamine (15.6 mg) was dissolved in water (500 µl), and MC-YR (500 µg) was dissolved in 5% K_2CO_3 (500 µl). The cysteamine solution (50 µl, followed by 100 µl at 30 min) was added to the MC-YR solution in portions. After about 2 h the reaction was acidified to pH 3 to 4 and applied to a reverse-phase flash column (4 × 1 cm). The column was eluted successively with water (10 ml), 10% MeOH (10 ml), 20% MeOH (10 ml), 30% MeOH (10 ml), 50% MeOH (2 × 10 ml), 70% MeOH (2 × 10 ml), and MeOH (3 × 10 ml). HPLC analysis indicated the product to be in the 50% MeOH and the first of the 70% MeOH fractions. These fractions were combined and the solvent removed *in vacuo* to yield MC-YR-cysteamine as a colourless solid (204 µg). ESI-MS *m/z* 1121.9 ($M-H^-$); ^1H, COSY and HMBC NMR spectra were consistent with the desired product.

Immunization of sheep and mice with ADDA-protein conjugates

Nine sheep and nine mice were immunised with the above BSA-ADDA-, cBSA-ADDA- and OVA-ADDA-conjugates (three animals for each conjugate). One mg of each conjugate in a volume of 1 ml phosphate buffer saline was added to Freund's complete adjuvants in case of the primary injection and homogenised to form an emulsion, and Freunds incomplete adjuvants in the case of booster injections. The animals received a minimum of three boosts in case of sheep, and six boosts in case of mice at approximately 4-week intervals.

ELISA

Indirect ELISA using polyclonal antibody #824

ELISA plates (NUNC MaxiSorp 1 #439454, Denmark) were coated with OVA-N-acetyl-D-alanyl-ADDA conjugate (OVA-ADDA-HG3/99') in 0.05 M sodium bicarbonate buffer pH 9.6 (75 µl, 2.5 µg/ml) overnight at 22 °C (RT). After a wash with PBS, additional binding sites were blocked by incubation with OVA (1/% w/v, 300 µl, 1 h, 20-25°C). Plates were washed two times with PBS and used immediately or stored at 4 °C for up to 7 days. In the assay, sample or standard (50 µl) was added to the wells together with antiserum (50 µl) at the appropriate

dilution (e.g. sheep serum #824$^{26/6/00}$ at 1/200 000; cf. Fig. 5). After incubation at 20-25 °C for 2 h, wells were washed twice with PBS + 0.05% Tween® 20 (PBST) and twice with PBS. Secondary antibody, horse radish peroxitase conjugated anti-species antibody, e.g. ICN/Cappel Anti-sheep-HRP (100µl, 1/6000), was then added to the wells and incubated for 2 h. Thereafter, wells were aspirated, washed twice with PBST and twice with PBS. TMB substrate solution, prepared by adding 110 µl TMB stock (10 mg/ml in DMSO) to 11 ml of sodium acetate buffer (0.1 M, pH 5.5) containing 0.005% H_2O_2, was then added and incubated for 15 minutes. The reaction was stopped by addition of H_2SO_4 (50 µl, 2 M), and the absorbance at 450 nm was determined with a microplate spectrophotometer. Standards and samples were prepared for ELISA by dilution in the following diluents: (i) methanol in PBS to a maximum methanol concentration of 10% (v/v); (ii) PBS; (iii) lake water (Lake Constance, Germany); (iv) tap water; (v) river water, Waikato River, New Zealand. All samples were analysed in at least duplicate, and over a range of dilutions.

ELISA method using antibody ADDA-#824$^{26/6/00}$ in detail

The principle of the indirect competitive microcystin ELISA (MC-ELISA) employed is shown in Fig. 4. This method comprises the following steps:

1. Prepare antigen (OVA-ADDA-HG$^{3/99}$) in bicarbonate buffer, pH 9.6 at 2.5 µg/ml (5 ml +/ plate).
2. Coat antigen onto microtitre plate at 75 µl/well, tap to mix and cover, incubate overnight at room temperature (RT, 22°C).
3. Wash two times in PBS, aspirate.
4. Block plate with 1% OVA (no. A-5503 from Sigma) (300 µl for 1 hour at RT (22 °C).
5. Wash two times in PBS, aspirate and use immediately or add 2-300 µl PBS for storage.

   The plates can be stored at this stage in PBS (at 4 °C) for up to 7 days.
6. Add 50 µl sample, or standard, in PBS;

   and 50 µl of antibody **ADDA- #824$^{26/6/00}$** (developed in sheep) at 1/200 000 dilution in OVA-blocker and incubate for 2 hours at RT (22 °C).

Standard curve: Primary 5000 ng/ml, then nine serial 1:8 dilutions (1 + 7) in 10%MeOH/PBS.

7. Wash two times in PBS/Tween, two times in PBS.
8. Add 100 µl of secondary antibody conjugate diluted in OVA (peroxidase-conjugated rabbit-anti-sheep IgG (ICN #55814) at a final dilution of 1/6000 and incubate for 2 hours at RT (22 °C).
9. Wash two times in PBST, two times in PBS, aspirate.
10. Turn on plate reader – needs a 15 minute warm up before reading at step 13.
11. Add 100 µl of substrate. Incubate for 15 minutes at RT (22 °C) until colour develops.
12. Add 50 µl stop solution (2M H_2SO_4).
13. Read absorbance at 450 nm. Note that the absorbance at 655 nm can be measured prior to adding the stop solution if required.

Direct ELISA using polyclonal antibody #825

ELISA plates (NUNC Maxisorp 1 # 439454, Denmark) were coated with the appropriate antiserum (#825[14/12/98]) in 0.05 M sodium bicarbonate buffer pH 9.6 (50 µl, 1/20 000) overnight at 20 °C. After a 2 x PBS wash, additional binding sites were blocked by incubation with BSA (1% w/v, 300 µl, 1 h, 20-25°C). Plates were washed two times with PBS and used immediately or stored at 4 °C for up to 7 days. In the assay, sample or standard (50 µl) was added to the wells together with the appropriate hapten-enzyme conjugate (50 µl, NH_2-ADDA-HRP[3/99], 200 ng/ml). After incubation at 20-25 °C for 3 hours, wells were washed twice with PBST and twice with PBS. TMB substrate solution, prepared by adding 110 µl TMB stock (10 mg/ml DMSO) to 11 ml sodium acetate buffer (0.1 M pH 5.5) containing 0.005% H_2O_2, was then added, followed by incubation for 15 minutes. The reaction was stopped by addition of H_2SO_4 (50 µl, 2 M), and the absorbance was determined with a microplate spectrophotometer at a wavelength of 450 nm. Standards and samples were prepared for ELISA by dilution in the following diluents: (i) methanol in PBS to a maximum methanol concentration of 10% (w/v); (ii) PBS; (iii) lake water (Lake Constance, Germany); (iv) tap water; (v) river water (Waikato River, New Zealand). All samples were analysed at least in duplicate

and over a range of dilutions.

Direct ELISA method in detail (example 99153005).

1. Prepare antiserum (#825, developed in sheep) in bicarbonate buffer pH 9.6 at 1/20 000 (5 ml\plate). Coat microtitre plate with 50 µl antiserum per well, tap to mix and cover, incubate overnight at room temperature (RT, 22 °C).
2. Wash 2 x PBS, aspirate.
3. Block plate with 1% BSA (300 µl for 1 h at RT (22 °C)).
4. Wash 2 x PBS, aspirate and use or add 200-300 µl PBS for storage. The plates can be stored at this stage in PBS (at 4 °C) for up to 7 days.
5. Add 50 µl sample, or standard in PBS, and 50 µl of hapten-enzyme conjugate (NH_2-ADDA-HRP) 200 ng/ml in BSA-blocker and incubate at room temperature for 3 hours at RT (22 °C).
   Standard curve primary 2000 ng/ml, then 9 serial 1:6 dilutions in PBS.
6. Wash 2 x PBST, 2 x PBS. Aspirate.
7. Turn on plate reader – needs a 15 minute warm up before reading at step 10.
8. Add 100 µl of substrate. Incubate at RT (22 °C) for 15 minutes.
9. Add 50 µl stop solution (2 M H_2SO_4).
10. Read absorbance at 450 nm. Note that the absorbance at 655 nm can be measured prior to adding the stop solution if required.

Results of the above-described test are illustrated in Fig. 6.

Indirect ELISA using monoclonal antibody #3G10B10 (assay 9910n001)

ELISA plates (NUNC MaxiSorp 1 #439454, Denmark) were coated with OVA-ADDA-HG conjugate in 0.05 M sodium bicarbonate buffer pH 9.6 (50 µl, 2.5 µg/ml) overnight at 20 °C. After a wash with PBS, additional binding sites were blocked by incubation with BSA (1/% w/v, 300 µl, 1 h, 20-25 °C). Plates were washed two times with PBS and used immediately or stored at 4 °C for up to 7 days. In the assay, sample or standard (50 µl) was added to the wells together with monoclonal antibody (50 µl) at the appropriate dilution (e.g. #3G10B10 at 1/750). After incubation at 20-25 °C for 2 h, wells were washed twice with PBS + 0.05%

Tween® 20 (PBST) and twice with PBS. After incubation at 20-25 °C for 2 h, wells were washed twice with PBS + 0.05% Tween™ 20 (PBST) and twice with PBS. Secondary antibody, horse radish peroxitase conjugated anti-species antibody, e.g. Silenus DAH anti-mouse-HRP (100 µl, 1/2000), was then added to the wells and incubated for 2 h. TMB substrate solution, prepared by adding 110 µl TMB stock (10 mg/ml in DMSO) to 11 ml of sodium acetate buffer (0.1 M, pH 5.5) containing 0.005% H_2O_2, was then added and incubated for 15 minutes. The reaction was stopped by addition of H_2SO_4 (50 µl, 2 M), and the absorbance at 450 nm was determined with a microplate spectrophotometer. Standards were prepared for ELISA by dilution in the methanol in PBS to a maximum methanol concentration of 10% (v/v). All samples were analysed at least in duplicate and over a range of dilutions.

Results of the above-described test are illustrated in Fig. 7.

<u>ELISA method using antibody #3G10B10 in detail</u>

The principle of the indirect competitive microcystin ELISA (MC-ELISA) employed is shown in Fig. 4. This method comprises the following steps:

1. Prepare antigen (OVA-ADDA-HG3199) in bicarbonate buffer, pH 9.6 at 2.5 µg/ml (5 ml/plate).
2. Coat antigen onto microtitre plate at 50 µl/well, tap to mix and cover, incubate overnight at room temperature (RT, 22 °C).
3. Wash two times in PBS, aspirate.
4. Block plate with 1% BSA – (300 µl for 1 hour at RT (22 °C)).
5. Wash two times in PBS, aspirate and use immediately or add 2-300 µl PBS for storage.

   The plates can be stored at this stage in PBS (at 4 °C) for up to 7 days.
6. Add 50 µl sample, or standard, in PBS;

   and 50 µl of antibody **#3G10B10** at 1/750 dilution in BSA-blocker and incubate for 2 hours at RT (22 °C).

   Standard curve: Primary 1000 ng/ml, then nine serial 1:4 dilutions (1 + 3) in PBS.

7. Wash two times in PBS/Tween, two times in PBS.
8. Add 100 µl of secondary antibody conjugate diluted in OVA (Horseradish peroxidase-conjugated rabbit-anti-mouse IgG (Silenus DAH) at a final dilution of 1/2000 and incubate for 2 hours at RT (22 °C).
9. Wash two times in PBST, two times in PBS, aspirate.
10. Turn on plate reader – needs a 15 minute warm up before reading at step 13.
11. Add 100 µl of substrate. Incubate for 15 minutes at RT (22 °C) until colour develops.
12. Add 50 µl stop solution (2M H_2SO_4).
13. Read absorbance at 450 nm. Note that the absorbance at 655 nm can be measured prior to adding the stop solution if required.

Preparation of buffers:

Bicarbonate coating buffer

Dissolve 0.85 g Na_2CO_3, (or 2.15 g $Na_2CO_3 \cdot 2\ H_2O$) and 1.47 g $NaHCO_3$ in 500 ml distilled water, adjust pH to 9.6 (gives 0.05 M bicarbonate).

Phosphate Buffered Saline (PBS)

To prepare 10 times stock solution:

$NaH_2PO_4 \cdot 2\ H_20$	2.897 g (or NaH_2PO_4 anhydrous 2.06 g)
Na_2HPO_4 anhydrous	11.938 g
NaCl	87.660 g

Weigh phosphates, add water to 800 ml, adjust pH to 7.4, then add salt.

Add water to 1 l and check pH (must be 7.2 to 7.6).

Dilute 1/10 for use: gives 0.01 M wrt phosphate and 0.15M NaCl.

Ref.: Mishell et al. (1980)

PBS/Tween

Suspend Tween-20 at 0.05% in PBS (0.5 ml/l);

Use for the washing steps desribed above.

OVA-blocking buffer

Dissolve OVA (Sigma A-5503) in PBS at 1% (2g/200ml).

Use for blocking plates, and as diluent for Ab and Ab".

Secondary antibody

Also referred to herein as Ab", HRP-conjugate, and Second Ab. The dilution depends on the batch used, but approximate dilutions are as follows:

ICN HRP-conjugated rabbit-anti-SHEEP-IgG #55814

Use at a working dilution of 1/3000. Stock solution is stored at 1/10 in PBS thiomersal (0.02%).

TMB Substrate

Prepare stocks of:

1) Sodium acetate buffer 0.1M, pH 5.5 (1.315g/200ml) (check for precipitate before use).

2) TMB (3,3',5,5'-tetramethylbenzidine) at 10mg/ml DMSO; [store in the dark at RT (22°C)].

Immediately before use:

Dissolve 110 µl TMB solution (2) in 11ml sodium acetate buffer (1), and, add 165 µl H_2O_2 (prepared freshly by diluting 38 µl 30% H_2O_2 (commercial strength) into 2.5 ml distilled H_2O).

ELISA Plates

96-well-plates were from NUNC (Maxisorp I plates, catalogue #439454).

Characterization of polyclonal anti-ADDA-antibody developed in sheep

The optimal concentrations of assay reagents were determined empirically by chequerboard titrations. Assay standard curves were calculated using Microsoft Excel. Cutoff values of 20 to 80% of maximum absorbance were used in order to determine the working range. Cross-reactivity of the assay was determined against congeners of MC-LR, -RR, -YR, -LW, -LF, desmethyl-MC-LR, desmethyl-MC-RR and nodularin and calculated from the concentration of analogue giving

50% inhibition (I_{50}) of binding to the protein-ADDA solid phase, expressed relative to the I_{50} for free microcystin-LR. The calculation of the cross-reactivity demonstrates that for sample concentrations ranging between 0.01 and 1 ng/ml the actual toxin concentrations are underestimated in the worst case by 5%. As of a sample concentration ranging betwee 1 ng/ml and 1 µg/l, most congeners tested are detected with equal sensitivity, i.e. 100% cross-reactivity (cf. Fig. 5), while the concentrations of MC-RR and nodularin are slightly overestimated (<5%). This demonstrates that microcystin and nodularin congeners can be detected reliably over a concentration range which is tenfold lower than the safe limit proposed by the WHO.

References

Beasley, V.R., Cook, W.O., Dahlem, A.M., Hooser, S.B., Lovell, R.A. and Valentine, W.M. (1989) Algae intoxication in livestock and waterfowl. *Veterinary Clinical North American (Food Anim. Pract.)*, **5**, 345-361.

Billings, W.H. (1981) Water-associated human illness in Northeast Pennsylvania and its suspected association with blue-green algae blooms. In W. W. Carmichael (eds.), *The Water Environment - Algal Toxins and Health*. Plenum Press, New York, pp. 243-255.

Botes, D.P., Kruger, H. and Viljoen, C.C. (1982a) Isolation and characterization of four toxins from the blue-green alga Microcystis aeruginosa. *Toxicon*, **20**, 945-954.

Botes, D.P., Viljoen, C.C., Kruger, H., Wessels, P.L. and Williams, D.H. (1982b) Configuration assignments of the amino acid residues and the presence N-methyldehydroalanine in toxins from the blue-green alga, Microcystis aeruginosa. *Toxicon*, **20**, 1037-1042.

Botes, D.P., Tuinman, A.A., Wessels, P.L., Viljoen, C.C., Kruger, H., Williams, D.H., Santikarn, S., Smith, R.J. and Hammond, S.J. (1984) The structure of cyanoginosin-LA, a cyclic heptapeptide toxin from the cyanobacterium Microcystis aeruginosa. *Journal of Chemical Society, Perkin Transactions*, **1**, 2311-2318.

Botes, D.P., Wessels, P.L., Kruger, H., Runnegar, M.T.C., Santikarn, S., Smith, R.J., Barna, J.C.J. and Williams, D.H. (1985) Structural studies on cyanoginosins-LR, -YR, -YA, and -YM, peptide toxins from Microcystis aeruginosa. *J. Chem. Soc. Perkin Trans.*, **1**, 2747-2748.

Carmichael, W.W., Mahmood, N.A. and Hyde, E.G. (1990) Natural toxins from cyanobacteria. In S. Hall and G. Strichartz (eds.), *Marine Toxins, Origin, Structure, and Molecular Pharmacology*. ACS, American Chemical Society, Washington, DC, pp. 87-106.

Carmichael, W.W. (1994) The toxins of cyanobacteria. *Scientific American*, **270**, 64-72.

Cousins, I.T., Bealing, D.J., James, H.A. and Sutton, A. (1996) Biodegradation of microcystin-LR by indigenous mixed bacterial populations. *Water Research*, **30**, 481-485.

Eriksson, J.E., Toivola, D., Meriluoto, J.A.O., Karaki, H., Han, Y.-G. and Hartshorne, D. (1990) Hepatocyte deformation induced by cyanobacterial toxins reflects inhibition of protein phosphatases. *Biochemical and Biophysical Research Communications*, **173**, 1347-1353.

Falconer, I.R., Jackson, A.R.B., Langley, J. and Runnegar, M.T.C. (1981) Liver pathology in mice in poisoning by the blue-green alga Microcystis aeruginosa. *Australian Journal of Biological Sciences*, **34**, 179-187.

Falconer, I.R., Beresford, A.M. and Runnegar, M.T.C. (1983) Evidence of liver damage by toxin from a bloom of the blue-green alga, Microcystis aeruginosa. *Medical Journal of Australia*, **1**, 511-514.

Falconer, I.R. (1991) Tumor promotion and liver injury caused by oral consumption of cyanobacteria. *Environmental Toxicology and Water Quality*, **6**, 177-184.

Falconer, I.R., Choice, A. and Hosja, W. (1992) Toxicity of edible mussels (Mytilus edulis) growing naturally in an estuary during a water bloom of the blue-green alga Nodularia spumigena. *Environmental Toxicology and Water Quality*, **7**, 119-123.

Francis, G. (1878) Poisonous Australian lake. *Nature*, **18**, 11-12.

Honkanen, R.E., Zwiller, J., Moore, R.E., Daily, S.L., Khatra, B.S., Dukelow, M. and Boynton, A.L. (1990) Characterization of microcystin-LR, a potent inhibitor of type 1 and type 2A protein phosphatases. *Journal of Biological Chemistry*, **265**, 19401-4.

Hooser, S.B., Kuhlenschmidt, M.S., Beasley, V.R., Carmichael, W.W. and Haschek, W.M. (1990) Mirocystin-LR uptake and localization in rat liver and hepatocyte suspensions (abstract). *Toxicologist*, **10**, 294.

Humphrey, J.M., Aggen, J. and Chamberlin, A.R. *J. Am. Chem. Soc.* **1996**, *118*, 11759-11770. "Synthesis of the Serine-threonine Phosphatase Inhibitor Microcystin LA."

Jackson, A.R.B., McInnes, A., Falconer, I.R. and Runnegar, M.T.C. (1984) Clinical and pathological changes in sheep experimentally poisoned by the blue-green alga Microcystis aeruginosa. *Veterinary Pathology*, **21**, 102-113.

James, H.A., James, C.P. and Hart, J. (1994) The analysis of microcystin-LR in water: Application in water treatment studies. In G. A. Codd, T. M. Jefferies, C. W. Keevil and E. Potter (eds.), *Detection methods for cyanobacterial toxins*. The Royal Society of Chemistry, Cambridge, pp. 51-58.

Keleti, G., Sykora, J.L., Maiolie, L.A., Doerfler, D.L. and Campbell, I.M. (1981) Isolation and characterization of endotoxin from cyanobacteria (blue-green algae). In W. W. Carmichael (eds.), *The Water Environment, Algal Toxins and Health*. Plenum Press, New York, pp. 447-464.

Kenefick, S.L., Hrudey, S.E., Peterson, H.G. and Prepas, E.E. (1993) Toxin release from Microcystis aeruginosa after chemical treatment. *Water Science and Technology*, **27**, 433-440.

Kondo, F., Ikai, Y., Oka, H., Okumura, M., Ishikawa, N., Harada, K.-I., Matsuura, K., Murata, H. and Suzuki, M. (1992) Formation, characterization, and toxicity of the glutathione and cysteine conjugates of toxic heptapeptide microcystins. *Chemical Research and Toxicology*. **5**, 591-596.

Lawton, L.A., Edwards, C. and Codd, G.A. (1994) Extraction and high-performance liquid-chromatographic method for the determination of microcystins in raw and treated waters. *Analyst*, **119**, 1525-1530.

MacKintosh, C., Beattie, K.A., Klumpp, S., Cohen, P. and Codd, G.A. (1990) Cyanobacterial microcystin-LR is a potent and specific inhibitor of protein phosphatases 1 and 2A from both mammals and higher plants. *FEBS Letters*, **264**, 187-92.

MacKintosh, R.W., Dalby, K.N., Campbell, D.G., Cohen, P.T., Cohen, P. and MacKintosh, C. (1995) The cyanobacterial toxin microcystin binds covalently to cysteine-273 on protein phosphatase 1. *FEBS Letters*, **371**, 236-240.

Mahmood, N.A., Carmichael, W.W. and Pfahler, D. (1988) Anticholinesterase poisonings in dogs from a cyanobacterial (blue-green algae) bloom dominated by Anabaena flos-aquae. *American Journal of Veterinary Research*, **49**, 500-503.

Mishell, B.B and Shiigi, S.M. (1980) Selected Methods in Cellular Immunology. Freeman & Co, San Francisco, page 458.

Matsushima, R., Yoshizawa, S., Watanabe, M.F., Harada, K., Furusawa, M., Carmichael, W.W. and Fujiki, H. (1990) In vitro and in vivo effects of protein phosphatase inhibitors, microcystins and nodularin, on mouse skin and fibroblasts. *Biochemical and Biophysical Research Communications*, **171**, 867-74.

Nishiwaki-Matsushima, R., Ohta, T., Nishiwaki, S., Suganuma, M., Kohyama, K., Ishikawa, T., Carmichael, W.W. and Fujiki, H. (1992) Liver tumor promotion by the cyanobacterial cyclic peptide toxin microcystin-LR. *Journal of Cancer Research and Clinical Oncology*, **118**, 420-424.

Rinehart, K.L., Harada, K.-I., Namikoshi, M., Chen, C., Harvis, C.A., Munro, M.H.G., Blunt, J.W., Mulligan, P.E., Beasley, B.R., Dahlem, A.M. and Carmichael, W.W. (1988) Nodularin, Microcystin, and the Configuration of ADDA. *Journal of the American Chemical Society*, **110**, 8557-8558.

Runnegar, M.T.C., Gerdes, R.G. and Falconer, I.R. (1991) The uptake of the cyanobacterial hepatotoxin microcystin by isolated rat hepatocytes. *Toxicon*, **29**, 43-51.

Runnegar, M., Berndt, N., Kong, S., Lee, E.Y.C. and Zhang, L. (1996) In vivo and in vitro binding of microcystin to protein phosphatases 1 and 2A (abstract). *Toxicologist*, **30**, 330.

Sherlock, I.R., Furey, A., James, K.J., Caudwell, F.B. and MacKintosh, C. (1998) New methods for the detection and identification of cyanobacterial toxins and their application to Irish freshwater. In: Reguera, B., Blanco, J., Fernandez, M.L., Wyatt, T. Harmful Algae, VIII International Conference, Vigo, Spain, 529-532.

Sivonen, K., Namikoshi, M., Evans, W.R., Carmichael, W.W., Sun, F., Rouhiainen, L., Luukkainen, R. and Rinehart, K.L. (1992a) Isolation and characterization of a variety of microcystins from seven strains of the cyanobacterial genus Anabaena. *Applied Environmental Microbiology*, **58**, 2495-500.

Sivonen, K., Namikoshi, M., Evans, W.R., Gromov, B.V., Carmichael, W.W. and Rinehart, K.L. (1992b) Isolation and structures of five microcystins from a Russian Microcystis aeruginosa strain CALU 972. *Toxicon*, **30**, 1481-5.

Sivonen, K., Skulberg, O.M., Namikoshi, M., Evans, W.R., Carmichael, W.W. and Rinehart, K.L. (1992c) Two methyl ester derivatives of microcystins, cyclic

heptapeptide hepatotoxins, isolated from Anabaena flos-aquae strain CYA 83/1. *Toxicon*, **30**, 1465-71.

Skulberg, O.M., Codd, G.A. and Carmichael, W.W. (1984) Toxic blue-green algal blooms in Europe: A growing problem. *Ambio*, **13**, 244-247.

Tencalla, F.G., Dietrich, D.R. and Schlatter, C. (1994) Toxicity of Microcystis aeruginosa peptide toxin to yearling rainbow trout (Oncorhynchus mykiss). *Aquatic Toxicology*, **30**, 215-224.

Tencalla, F. (1995) Toxicity of cyanobacterial peptide toxins to fish. Ph.D. Thesis, ETH Zürich.

Theiss, W.C., Carmichael, W.W., Wyman, J. and Bruner, R. (1988) Blood pressure and hepatocallular effects of the cyclic heptapeptide toxin produced by the freshwater cyanobacterium (blue-green alga) Microcystis aeruginosa strain PCC-7820. *Toxicon*, **26**, 603-613.

Tisdale, E.S. (1931) Epidemic of intestinal disorders in Charleston, W. VA., occurring simultaneously with umprecedented water supply conditions. *American Journal of Public Health*, **21**, 198-200.

Tsuji, K., Naito, S., Kondo, F., Ishikawa, N., Watanabe, M.F., Suzuki, M. and Harada, K.-I. (1994) Stability of microcystins from cyanobacteria: Effect of light on decompostition and isomerization. *Environmental Science and Technology*, **28**, 173-177.

Watanabe, M.M., Kaya, K. and Takamura, N. (1992a) Fate of the toxic cyclic heptapeptides, the microcystins, from blooms of Microcystis (cyanobacteria) in a hypertrophic lake. *Journal of Phycology*, **28**, 761-767.

Watanabe, M.F., Tsuji, K., Watanabe, Y., Harada, K.-I. and Suzuki, M. (1992b) Release of heptapeptide toxin (microcystin) during the decomposition process of Microcystis aeruginosa. *Natural Toxins*, **1**, 48-53.

Wicks, R.J. and Thiel, P.G. (1990) Environmental factors affecting the production of peptide toxins in floating scums of the cyanobacterium Microcystis aeruginosa in a hypertrophic African reservoir. *Environmental Science and Technology*, **24**, 1413-1418.

Yoshizawa, S., Matsushima, R., Watanabe, M.F., Harada, K.-I., Ichihara, A., Carmichael, W.W. and Fujiki, H. (1990) Inhibition of protein phosphatases by microcystin and nodularin associated with hepatotoxicity. *Journal of Cancer Research and Clinical Oncology*, **116**, 609-614.

Applicant: Prof. Dr. Daniel R. Dietrich et al.
" Congener Independent Detection Of Microcystin And Nodularin Congeners "
Our Ref: D 2681EU - py / js

Claims

1. A proteinaceous compound or functionally active derivative or part thereof having a binding site for a group represented by the following formula (I)



(I)

which is part of a toxin derived from a cyanobacterium, wherein
group R^1 represents a halogen atom, $-OSO_3$, -OR' or $-NR'_2$ and
group R^2 represents hydrogen, (C_1-C_4)alkyl, (C_1-C_4)alkoxy, (C_1-C_4)acyl, (C_1-C_4)aminoacyl or (C_1-C_4)carboxyaminoacyl,
or the groups R^1 and R^2 are connected to each other to form a cyclic moiety,
the groups R^3 which may be the same or different are each independently selected from the group consisting of hydrogen and (C_1-C_4)alkyl,
group R^4 represents (C_1-C_4)alkoxy,
and wherein the phenyl group may be substituted or unsubstituted.

2. The proteinaceous compound of claim 1, wherein the groups R' represent independently from each other hydrogen, substituted or unsubstituted (C_1-C_4)alkyl or (C_1-C_4)acyl, when bound to nitrogen.

3. The proteinaceous compound of claim 1 or 2, wherein the groups R^3 each represent methyl and group R^4 represents methoxy.

4. The proteinaceous compound according to any one of claims 1 to 3, wherein group R^1 represents aminoacyl and group R^2 represents (C_1-C_4)acyl.

5. The proteinaceous compound of claim 4, wherein group R^1 represents glycyl or D-alanyl and group R^2 represents acetyl.

6. The proteinaceous compound according to any one of claims 1 to 5, wherein group R^1 represents $-NH_2$ and group R^2 represents glutamidyl or 2-aminopropionamidyl.

7. The proteinaceous compound according to any one of claims 1 to 6, wherein the toxin is selected from the group consisting of mycrocystin and nodularin congeners.

8. The proteinaceous compound according to any one of claims 1 to 7 which is a polyclonal, monoclonal or recombinant antibody or a functionally active derivative or fragment thereof.

9. A method for the preparation of the proteinaceous compound according to any one of claims 1 to 8 comprising the steps of
   (a) preparing a compound containing a group represented by formula (I) as defined in any one of claims 1 to 7, and
   (b) coupling the compound of step (a) to a carrier.

10. The method of claim 9, wherein the carrier is selected from the group consisting of polyethyleneglycol, polypeptides, proteins, polysaccharides or plastic supports.

11. The method of claim 10, wherein the protein carrier is selected from bovine serum albumin, ovalbumin, cationised bovine serum albumin or horseradish peroxidase.

12. The method according to any one of claims 9 to 11 which further comprises the steps of
   (c) immunizing an animal with the conjugate obtained in step (b), and
   (d) isolating the animal's blood, blood serum and/or spleenocytes.

13. A diagnostic kit containing the proteinaceous compound according to any one of claims 1 to 8.

14. An affinity matrix containing the proteinaceous compound according to any one of claims 1 to 8 coupled to a polymeric resin.

15. Use of the proteinaceous compound according to any one of claims 1 to 8 for the detection of a compound containing the group represented by the formula (I).

16. A method for concentrating a compound containing the group represented by the formula (I) from a fluid or for substantially decreasing the amount of a compound containing the group represented by the formula (I) in a fluid comprising the steps of

(a) preparing the proteinaceous compound according to any one of claims 1 to 8,

(b) coupling the compound obtained in step (a) to a polymeric matrix, and

(c) contacting the fluid with the polymeric matrix obtained in step (b).

17. The method of claim 16, wherein the fluid is hemodialysis water, drinking water or water derived from rivers, lakes and oceans.

Preparation of Anti-ADDA Antibody



Fig. 1

Antibodies to the region of the molecule enclosed in the box are desired. Therefore, this part has been kept constant and the chemistry which is used to couple the the ADDA-hapten to the protein has to be varied in order to yield a suitable immunogen and antigen



N-Ac-ADDA-Gly-OH (1)



Glutarate derivative of amine

Fig. 2

ADDA-Derivatives	
	Alkyne precursor MW 202.32
	"Vinyliodide" precursor MW 369.23
	"ADDA", N-acetyl, D-ala, methyl ester MW 458.65
	"ADDA", N-acetyl, free acid MW 373.54
	"ADDA" N-acetyl, methyl ester MW 387.57
	"ADDA", BOC-amine, methyl ester MW 445.66
	"ADDA", BOC-amine, free acid MW 431.63

Fig. 3


Indirect Competitive MC-ELISA
Well coating with antigen
Block
Block
Incubation with primary antibody including more or less sample
Wash
Wash
Incubation with detection antibody conjugated to HRP
Wash
Wash
Substrate added and inhibition of color change measured
Protein-toxin conjugate
Detection antibody
Toxin sample
Primary antibody

Fig. 4


Microcystin-ADDA cross reactivity curves
Microcystin- ADDA cross reactivity curves vs 824(26/06/00) at 1:2x10^5;
OVA-ADDA at 2.5ug/ml,(75ul/well),ICN/Cappel at 1:6000
J2408001-2 and J2208001-2
Absorbance % Bo (450nm)
Congener concentration (ng/ml)
MC-LR
nodularin
MC-RR
MC-LW
DM-LR
MC-YR
MC-LF
DM-RR

Fig. 5


HRP-MC-YR Direct assay
HRP-MC-YR conjugate prepared 3/99 Standard Curve MC-YR in PBS
Plate coater Sheep 825bled, 14/12/98 at 1:20000, Blocker 1% BSA/PBS
99153005
NH2-HRP-ADDA @ 200ng/ml
Absorbance (450nm)
2,5
2
1,5
1
0,5
0
0,000001 0,00001 0,0001 0,001 0,01 0,1 1 10 100 1000 10000
Microcystin YR Concentration (ng/ml). Titration values are [conjugate] (ng/ml)

Fig. 6


Competition Curve of MYCR Using the 3G10 B10 Mouse Monoclonal Antibody
OVA-ADDA-HG3/99' at 2.5ug/ml, Blocked 1%OVA/PBS0.45um filtered 10/11/99, 3G10 B10 at 1:750, Silenus
Antimouse-HRPTG21A at 1:2000
9910n001
MCYR (ex Konstanz)
Absorbance (450nm)
1,2
1
0,8
0,6
0,4
0,2
0
0,0001
0,001
0,01
0,1
1
10
100
1000
Concentration (ng/ml)

Fig. 7